1. Do hospitals that participate in COVID-19 research differ from non-trial hospitals? A cross-sectional study of US hospitals
- Author
-
Kang, Daniel, Huang, Cher X, Yuen, Alexander D, Norris, Keith C, and Vijayan, Tara
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Clinical Trials and Supportive Activities ,Infectious Diseases ,Clinical Research ,Emerging Infectious Diseases ,Good Health and Well Being ,Humans ,COVID-19 ,Cross-Sectional Studies ,Hospitalization ,Hospitals ,Research Design ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Cardiovascular System & Hematology ,General & Internal Medicine ,Clinical sciences ,Epidemiology ,Health services and systems - Abstract
ObjectivesTo compare hospitals that did and did not participate in clinical trials evaluating potential inpatient COVID-19 therapeutics.MethodsWe conducted a cross-sectional study of hospitals participating in trials that were registered on clinicaltrials.gov between April and August 2020. Using the 2019 RAND Hospital Dataset and 2019 American Community Survey, we used logistic regression modeling to compare hospital-level traits including demographic features between trial and non-trial hospitals.ResultsWe included 488 hospitals that were participating in 298 interventional trials and 4232 non-participating hospitals. After controlling for demographic and other hospital traits, we found that teaching status (OR 2.11, 95% CI 1.52-2.95), higher patient acuity (OR 7.48, 4.39, 13.1), and location in the Northeast (OR 1.83, 95% CI 1.18, 2.85) and in wealthier counties (OR: 1.32, 95% CI 1.16-1.51) were associated with increased odds of trial participation, while being in counties with more White residents was associated with reduced odds (OR 0.98, 95% CI 0.98-0.99).ConclusionsHospitals participating and not participating in COVID-19 inpatient treatment clinical trials differed in many ways, resulting in important implications for the generalizability of trial data.
- Published
- 2023